** Co said on Friday the U.S health regulator had declined to issue Emergency Use Authorization $(EUA.UK)$ for Niyad, a device used to deliver co's blood thinner nafamostat
** The FDA said review of co's EUA not a priority due to volume of EUA requests
** Co said it expects to submit a premarket application for Niyad to the FDA in 2024
** Including session moves, shares down 72.3% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.